Ryoma Yoshiki, Moriya Yoichiro, Okamoto Masato, Kanaya Isao, Saito Motoo, Sato Mitsunobu
Product Lifecycle and Medical Information Division, Chugai Pharmaceutical Co., Ltd. 2-1-9 Kyobashi, Chuo-ku, Tokyo, Japan.
Anticancer Res. 2004 Sep-Oct;24(5C):3295-301.
OK-432 (Picibanil), a streptococcal preparation with potent biological response modifying activities, was approved in Japan as an anticancer agent in 1975. In the ensuing 30 years, since then, a significant amount of data, including clinical as well as experimental studies, has been accumulated. OK-432 has been reported to induce various cytokines, activate immunological cells and thus augment anticancer immunity. Recently, the interrelation between innate immunity and adaptive immunity has become clear and it was reported that OK-432 acts, at least in part, via Toll-like receptor (TLR) 4-MD2 signaling pathway. In addition, dendritic cells (DCs) are considered to play a pivotal role in immunological response and it is reported that OK-432 induced maturation of DCs both in vitro and in vivo. These results suggest that OK-432 is a useful adjuvant in DC-based anticancer immunotherapy. Clinical studies of DC therapy with OK-432 are under way.
OK-432（溶链菌制剂）是一种具有强大生物反应调节活性的链球菌制剂，于1975年在日本被批准作为抗癌药物。从那时起的30年里，积累了大量数据，包括临床和实验研究。据报道，OK-432可诱导多种细胞因子，激活免疫细胞，从而增强抗癌免疫力。最近，固有免疫和适应性免疫之间的相互关系已变得清晰，并且有报道称OK-432至少部分通过Toll样受体（TLR）4-MD2信号通路发挥作用。此外，树突状细胞（DCs）被认为在免疫反应中起关键作用，并且有报道称OK-432在体外和体内均可诱导DCs成熟。这些结果表明，OK-432在基于DC的抗癌免疫治疗中是一种有用的佐剂。目前正在进行使用OK-432的DC治疗的临床研究。
